Literature DB >> 28645470

Significance of Atrial Fibrillation Complicating ST-Segment Elevation Myocardial Infarction.

Tomasz Podolecki1, Radoslaw Lenarczyk2, Jacek Kowalczyk2, Ewa Jedrzejczyk-Patej2, Andrzej Swiatkowski2, Piotr Chodor2, Agnieszka Sedkowska2, Witold Streb2, Katarzyna Mitrega2, Zbigniew Kalarus3.   

Abstract

The aim of the present study is to assess the clinical impact of atrial fibrillation (AF) in patients with ST-segment elevation myocardial infarction (STEMI) complicated by new-onset AF depending on STEMI location and timing of arrhythmia. We analyzed 4,363 consecutive STEMI patients treated invasively. Finally, 4,099 subjects were included into further analysis, as 264 patients were excluded because of previous AF history. In total, 1,800 (43.9%) subjects with anterior infarction were included into Group 1, whereas Group 2 encompassed 2,299 (56.1%) patients with nonanterior infarction. Subsequently, both groups were divided into patients with new-onset AF (AF Group 1 and 2, respectively) and without AF (Control Group 1 and 2). New-onset AF was recognized in 225 patients (5.5%): 96 (5.3%) with an anterior wall infarction (AF Group 1) and 129 (5.6%) with a nonanterior wall infarction (AF Group 2). The incidence of early-onset arrhythmia (within 24 hours after admission) was significantly higher in AF Group 2 than in AF Group 1: 71.3% versus 35.4% (p <0.001). In Group 1, both early- and late-onset AFs were associated with significantly increased in-hospital mortality compared with AF-free population (17.7% and 27.4%, respectively vs 6.3%; p <0.05), whereas in Group 2, in-hospital mortality was increased only in subjects with late-onset AF compared with AF-free population (13.5% vs 4.2%, p <0.05). New-onset AF was the independent predictor of death only in Group 1 (hazard ratio 2.16) and this effect was stronger for late-onset AF (hazard ratio 2.86). In conclusion, 1 in 20 patients with STEMI treated invasively was affected by new-onset AF. The predictive value of new-onset AF was strongly related with STEMI location and timing of arrhythmia.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28645470     DOI: 10.1016/j.amjcard.2017.05.017

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Baseline atrial fibrillation is associated with contrast-induced nephropathy after cardiac catheterization in coronary artery disease: Systemic review and meta-analysis.

Authors:  Narut Prasitlumkum; Chanavuth Kanitsoraphan; Veraprapas Kittipibul; Pattara Rattanawong; Pakawat Chongsathidkiet; Wisit Cheungpasitporn
Journal:  Clin Cardiol       Date:  2018-11-26       Impact factor: 2.882

Review 2.  Exosomes and Exosomal Non-coding RNAs Are Novel Promises for the Mechanism-Based Diagnosis and Treatments of Atrial Fibrillation.

Authors:  Chaofeng Chen; Qingxing Chen; Kuan Cheng; Tian Zou; Yang Pang; Yunlong Ling; Ye Xu; Wenqing Zhu
Journal:  Front Cardiovasc Med       Date:  2021-12-01

3.  New-Onset Atrial Fibrillation in Acute Myocardial Infarction Is a Different Phenomenon than Other Pre-Existing Types of That Arrhythmia.

Authors:  Monika Raczkowska-Golanko; Krzysztof Młodziński; Grzegorz Raczak; Marcin Gruchała; Ludmiła Daniłowicz-Szymanowicz
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

4.  New-onset paroxysmal atrial fibrillation in acute myocardial infarction: increased risk of stroke.

Authors:  Ji Hyun Lee; Sun-Hwa Kim; Wonjae Lee; Youngjin Cho; Si-Hyuck Kang; Jin Joo Park; Il-Young Oh; Chang-Hwan Yoon; Jung-Won Suh; Young-Seok Cho; Tae-Jin Youn; In-Ho Chae; Dong-Ju Choi
Journal:  BMJ Open       Date:  2020-09-23       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.